Contrast Agent, Liquid Biopsy Tool Or Treatment? Earli Might Deliver All Three At Once
The company has developed a technology that uses engineered DNA to reprogram cancer cells, forcing them to produce substances that could be used to help image, detect or even destroy them.
You may also be interested in...
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Less than a month after it sold off its reproductive health assets, Invitae has filed for bankruptcy. That will not come as a surprise to anyone following the company.
Freenome, the Roche-backed early cancer detection liquid biopsy developer has raised yet more money, making it one of the best-funded companies in its sub-sector. With trial results due relatively soon, investors are likely hoping this will be the last funding round required before full commercialization.